Sacubitril/valsartan can improve the cardiac function in heart failure patients with a history of cancer: An observational study

  • Published on 06/10/2024
  •  Reading time: 7 min.

Chen, Zhulua; Zhang, Chuan Phda; Zhu, Yuxi Phdb; Gao, Diansa Phda; Mao, Min Phda; Zuo, Zhong Phda,*


Sacubitril/Valsartan, the combination of angiotensin receptor inhibitor and neprilysin inhibitor, is now becoming the class 1 recommendation for HFrEF. Some studies have shown the positive effect of Sacubitril/Valsartan on HFrEF cancer patients, while there is devoid of evidence about the effect of this drug in aged cancer patients with HFmrEF and HFpEF. By searching the patients with a diagnosis of both...


To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Cardiology

Receive our newsletter to stay up to date with the latest news in Cardiology